aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.
Company profile
Ticker
AVTE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aerovate Securities Corporation ...
IRS number
831377888
AVTE stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
27 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
25 Mar 24
S-8
Registration of securities for employees
8 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Topline Phase 2b data expected in June 2024
20 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
14 Aug 23
Latest ownership filings
144
Notice of proposed sale of securities
17 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
George A Eldridge
12 Apr 24
4
DAVID S. GRAYZEL
11 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
4
TIMOTHY P NOYES
3 Apr 24
4
Benjamin T Dake
3 Apr 24
4
Marinus Verwijs
3 Apr 24
4
George A Eldridge
3 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.18 mm | 32.18 mm | 32.18 mm | 32.18 mm | 32.18 mm | 32.18 mm |
Cash burn (monthly) | 9.57 mm | (no burn) | 7.12 mm | 6.27 mm | 5.20 mm | 4.74 mm |
Cash used (since last report) | 63.56 mm | n/a | 47.29 mm | 41.61 mm | 34.55 mm | 31.45 mm |
Cash remaining | -31.38 mm | n/a | -15.11 mm | -9.43 mm | -2.37 mm | 728.97 k |
Runway (months of cash) | -3.3 | n/a | -2.1 | -1.5 | -0.5 | 0.2 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 63 |
Opened positions | 4 |
Closed positions | 9 |
Increased positions | 23 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 487.44 bn |
Total shares | 37.37 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 8.26 mm | $141.73 bn |
Sofinnova Investments | 3.76 mm | $64.46 bn |
Sofinnova Venture Partners X | 3.76 mm | $72.81 mm |
Atlas Venture Associates XII | 3.10 mm | $61.89 mm |
TCG Crossover Management | 2.20 mm | $37.75 bn |
Atlas Venture Fund XII | 2.04 mm | $62.24 mm |
Atlas Venture Life Science Advisors | 2.04 mm | $34.97 bn |
Baker Bros. Advisors | 1.96 mm | $33.67 bn |
Cormorant Asset Management | 1.56 mm | $26.78 bn |
Driehaus Capital Management | 1.19 mm | $20.48 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 24 | George A Eldridge | Common Stock | Sell | Dispose S | No | Yes | 27.5646 | 771 | 21.25 k | 1,960 |
10 Apr 24 | George A Eldridge | Common Stock | Sell | Dispose S | No | Yes | 26.7706 | 6,729 | 180.14 k | 2,731 |
10 Apr 24 | George A Eldridge | Common Stock | Option exercise | Acquire M | No | Yes | 2.14 | 7,500 | 16.05 k | 9,460 |
10 Apr 24 | George A Eldridge | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 2.14 | 7,500 | 16.05 k | 43,763 |
9 Apr 24 | Grayzel David S. | Common Stock | Sell | Dispose S | Yes | No | 28.15 | 11,882 | 334.48 k | 14,502 |
1 Apr 24 | Benjamin T Dake | Common Stock | Sell | Dispose S | No | Yes | 31.9749 | 3,325 | 106.32 k | 1,291 |
1 Apr 24 | Benjamin T Dake | Common Stock | Option exercise | Acquire M | No | Yes | 10.61 | 3,325 | 35.28 k | 4,616 |
1 Apr 24 | Benjamin T Dake | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 10.61 | 3,325 | 35.28 k | 25,675 |
1 Apr 24 | George A Eldridge | Common Stock | Sell | Dispose S | No | Yes | 31.2291 | 12,495 | 390.21 k | 1,960 |
1 Apr 24 | George A Eldridge | Common Stock | Option exercise | Acquire M | No | Yes | 2.14 | 12,495 | 26.74 k | 14,455 |
News
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
5 Apr 24
Wells Fargo Maintains Overweight on Aerovate Therapeutics, Maintains $35 Price Target
1 Apr 24
Aerovate Therapeutics To Present Patient Baseline Characteristics Of The Phase 2b Portion Of The Phase 2b/Phase 3 IMPAHCT Trial At The American Thoracic Society 2024 International Conference
27 Mar 24
Recap: Aerovate Therapeutics Q4 Earnings
25 Mar 24
Aerovate Therapeutics Q4 2023 GAAP EPS $(0.74) Misses $(0.70) Estimate
25 Mar 24